MIAMI, June 27, 2013 /PRNewswire/ -- Fuisz Pharma LLC today announced the filing of a patent addressing the consolidation of metadata from a bodily fluid analyzer and the presentation of that data to a physician or caregiver.
Richard C. Fuisz, M.D., commented: "The potential proliferation of home analyzers presents the very real prospect of data overload particularly in the context of today's increasingly burdened practicing physicians. Historically, clinicians have not reviewed real-time data outside of the most singularly acute patient care context.
The intention with this invention is to consolidate, interpret and present data in a novel way that is relevant to patient care and has a realistic approach to the physician's time constraints. Unless we can make data available to clinicians in ways that fit with and complement modern medical practice, we will not capture the benefits of technical advances in sensor capabilities.
Patients are not toasters. They require individual attention in a fast and concise manner from their doctors. That means doctor friendly data. We cannot substitute algorithmic-driven server based conclusions for the doctor's art.
This invention also provides for the ability of patients to opt-in and to be reimbursed for the use of their data for more general research purposes. Patients deserve the respect of choice and indeed remuneration so their use of a device does not turn them into unwitting, unpaid participants in the grander schemes of a data-driven industry."
Dr. Richard Fuisz is founding member of Fuisz Pharma LLC (http://en.wikipedia.org/wiki/Richard_Fuisz).
Joseph M. Fuisz, a co-inventor on the application, remarked: "This application is not limited solely to data presentation to clinicians but also includes certain advances in data management that relate to the ultimate use of large amounts of personal data, and participation by patients in the benefits resulting from it."
Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma is also active in diagnostic systems. Fuisz Pharma has its headquarters in Miami and is not affiliated with MonoSol Rx. www.fuisz.com.
SOURCE Fuisz Tobacco LLC